-
Study aim
-
Comparative study of the outcome of assisted reproductive therapy using double recombinant HCG injection and HCG injection (alone and in combination with GNRH) in patients with poor response in the ovulation stimulation cycle (IVF / ICSI).
-
Design
-
Clinical trial with control group, with parallel groups, double-blind, randomized, phase 3 on 150 patients in three groups. Being the number of people in each group, we will use the Restricted randomization method of the block randomization method, so that from 15 blocks of 6, including 2 to A, 2 to B and 2 to C Will be formed.
-
Settings and conduct
-
People start gonadotropin on the third day after menstruation after ovulation. To perform oocyte triggering, patients are randomly divided into three groups. Isfahan Shahid Beheshti Hospital.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Bologna Criteria people
Exclusion criteria: Patients who become infected with the coronavirus during the cycle, patients who have not responded appropriately to the ovulation stimulation cycle and do not actually have a follicle to empty, patients who have mistakenly taken drugs during the cycle.
-
Intervention groups
-
People receive gonadotropin from the third day of menstruation by stimulating ovulation after being in the IVF cycle.In the first group, HCG trigger with KARMA brand is given alone with a dose of 10,000 units. In the second group, HCG trigger with KARMA brand is mentioned in the amount of 5000 units with GNRHagonist with Decapeptyl 0.2 brand and in the third group, recombinant HCG with OVITREEL brand with a dose of 250 micrograms is given twice in 12 hours.
-
Main outcome variables
-
Comparison of the average number of oocytes obtained and the rate of chemical pregnancy, frequency of IMPLANTATION, frequency of CILINICAL PREGNANCY, frequency of ONGOING PREGNANCY is used in three study groups.